AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options...
PR Newswire·2d ago
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
Zacks·3d ago
Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?
ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.
Zacks·6d ago
Pharmaceutical Tariffs ‘A Light At The End Of The Trump Tunnel’ For Big Pharma, Says Jefferies
The analyst noted that several large-cap pharmaceutical companies have already announced plans to build U.S. manufacturing facilities.
Stocktwits·6d ago
AbbVie (ABBV) Declines More Than Market: Some Information for Investors
AbbVie (ABBV) concluded the recent trading session at $219.99, signifying a -1.18% move from its prior day's close.
Zacks·7d ago
Boost Your Portfolio With These Top-Ranked ETFs
With the Fed's first 2025 rate cut and upgraded growth outlook, ETFs in tech, financials, industrials and health care could benefit from momentum.
Zacks·13d ago
The Zacks Analyst Blog Highlights AbbVie, ServiceNow, Boeing, Tucows and and Ampco-Pittsburgh
Zacks spotlights AbbVie, ServiceNow, Boeing, Tucows, and Ampco-Pittsburgh, detailing growth drivers, headwinds, and industry positioning.
Zacks·13d ago
Top Analyst Reports for AbbVie, ServiceNow & Boeing
AbbVie, ServiceNow, and Boeing outpace their industries as analysts highlight growth drivers and risks in fresh research reports.